Search Results for: GLOBAL REPORT 2017 Global Drug
Articles
GALECTIN-DIRECTED THERAPIES - Targeting Galectin-3 Protein in Drug Development May 1, 2017
Peter G. Traber, MD, believes we are only at the beginning of understanding the full potential of gal-3 targeted therapy, and the future likely holds additional high affinity, specific, galectin inhibitors that are bioavailable by routes other than the two currently in development.
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer April 18, 2017
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for...Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer April 18, 2017
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for...ANTIMICROBIAL LIPIDS - Attenuating the Use of Medically Important Antimicrobial Drugs in Food-Producing Animals: What Role Can cGMP Lipids Play? April 3, 2017
Ryan Littich, PhD, highlights some of the most significant, pathogen-borne diseases relevant to food-producing animals and reviews the antimicrobial properties intrinsic to midchain triglyceride lipolysis products.
SPECIAL FEATURE - Bioavailability & Solubility: New Approaches to Enhance Drug Performance February 27, 2017
Contributor Cindy H. Dubin highlights many of the latest techniques to enhance bioavailability and solubility, how to determine the right technique for your compound, and how some companies are realizing faster time to market as a result.
Roche to Gain Most as Biogen Remains Leader in Neurodegenerative Drugs Market February 20, 2017
Roche will be the biggest mover in the neurodegenerative drugs space throughout the next 5 years, with the anticipated approval...Next-Generation Silicone Adhesive Technologies Key to Broader Global Adoption, Growth of Wearable Medical Devices February 8, 2017
According to Grand View Research, the global market for wearable medical devices is expected to reach $27.8 billion by 2022.1...Global Urological Cancers Market Will Double to $35.9 billion by 2022 July 11, 2016
The urological cancers market, including bladder, kidney, prostate, and testicular cancer, will increase from $17.9 billion in 2015 to $35.9...Global Non-Small Cell Lung Cancer Treatment Market Value to Approach $11 Billion September 8, 2015
The global market value for Non-Small Cell Lung Cancer (NSCLC) treatment will increase from $6.9 billion in 2014 to $10.9...Key Patent Expiries to Lead Global Anti-Hypertensive Market June 10, 2014
Multiple major drug patent expiries will cause the global anti-hypertensive market value to decline from $40 billion in 2013 to...Bladder Cancer Market to Witness Moderate Growth by 2017 April 8, 2014
The bladder cancer therapeutics market in the six major countries (6MM) - the US, France, Germany, Italy, Spain, and UK...Bladder Cancer Market to Witness Moderate Growth by 2017 January 24, 2014
The bladder cancer therapeutics market in the six major countries (6MM) - the US, France, Germany, Italy, Spain, and UK...North American Drug Delivery Technologies Market Worth $102.2 Billion by 2017 October 14, 2013
Patent expiry of major blockbuster drugs is a prime concern for pharmaceutical companies, as developing a new chemical entity (NCE)...SPECIAL REPORT - Prefilled Syringes & Parenteral Contract Manufacturing: Improving for Flexibility & Customization April 30, 2013
Special Feature: Contributor Cindy H. Dubin speaks with prefilled syringe manufacturers as well as contract parenteral manufacturers who share their thoughts about the delivery challenges associated with high-viscous, high-volume formulations.
CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges January 26, 2024
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
SOLUBILIZING & STABILIZING TECHNOLOGY - CAPTISOL® - Part Perseverance & Part Serendipity October 2, 2023
Vince Antle, PhD, James Pipkin, PhD, and Lian Rajewski, PhD, say with decades of experience, proven safety, and recent and forthcoming authorizations in several new routes of delivery, the Captisol Team is looking forward to the next 2 decades and more of new drug products, new applications, and continued improvement in the technology.
ANTI-VIRAL RESEARCH - Anti-Viral Activity of Pimpinella anisum Extract In Vitro Study June 5, 2023
Fouad Al-Bayaty, Mazen M. Jamil Al-Obaidi, Maryam Haki Al-Doori, and Omar Imad present a study conducted to evaluate the antiviral effectiveness of Pimpinella anisum against dengue virus.
Multiple Sclerosis Market to Generate Sales of $29.8 Billion by 2030 April 18, 2023
The market for multiple sclerosis (MS) disease-modifying therapies (DMT) is set to experience moderate growth across the seven major markets...SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame March 1, 2023
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
AUTOINJECTOR TECHNOLOGY - De-risking Biosimilar Development With a Clinically Validated & Commercially Proven Disposable Autoinjector June 1, 2022
Victoria Meyer, MBA, explains how for many biopharmaceutical customers, BD and the BD Physioject™ Disposable Autoinjector have offered the appropriate combination of technology, documentation, and resources required for timely success.
